Bexxar Retreatment, Leukemia Reports Among Corixa’s Phase IV Studies

Corixa will examine the retreatment effects of Bexxar patients who have had a duration of response against non-Hodgkin's lymphoma of at least six months as part of its Phase IV commitments for the oncologic